The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow-up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI)
0.61-0.90); p 5 0.002] and OS (AHR, 0.75; 95% CI, 0.60-0.94; p 5 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65-1.08; p 5 0.165). SLN-negative patients had better 5-and 10-year MSS compared with SLN-positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p 5 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.
The role of sentinel lymph node (SLN) biopsy in cutaneous melanoma is best defined in patients with tumors of intermediate thickness (Breslow index ranged 1-4 mm), for whom the only clinical trial conducted to date-the Multicenter Selective Lymphadenectomy Trial (MSTL-I)-showed a benefit for disease-free survival (DFS) but not for melanomaspecific survival (MSS) 1 although recent clinical trials have not shown a benefit of subsequent lymphadenectomy in patients with positive SLN biopsy. 2, 3 The clinical utility of SLN biopsy for melanomas measuring over 4 mm is less clear. The MSTL-I also studied 290 patients with thick melanomas (>3.5 mm) who underwent SLN biopsy, and revealed similar findings to those reported for intermediate-thickness tumors, ie, there was a benefit for DSF but not for MSS. More recent observational studies on the therapeutic role of SLN biopsy in thick melanomas, however, have described controversial results. While some have reported similar results to the MSLT-I (no increase in MSS), 4 others have suggested that the procedure might have some therapeutic effect in this subgroup of patients. 5, 6 The primary aim of this study was to investigate whether performance of SLN biopsy increases MSS in patients with thick melanomas (>4 mm).
Secondary aims were to compare DFS and overall survival (OS) between cohorts and evaluate DFS and MSS in patients who underwent SLN biopsy according to SLN status (positive or negative).
Material and Methods

Study design
We conducted a multicenter, retrospective, observational study using prospectively collected data for patients with melanomas measuring over 4 mm in thickness in 5 tertiary hospitals, including 4 in Spain (Hospital Universitari Germans Trias i Pujol in Badalona, Barcelona; Hospital Cl ınic in Barcelona; Instituto Valenciano de Oncolog ıa in Valencia; and Hospital Universitario Virgen Macarena in Sevilla) and 1 in Italy (Universit a di Torino in Turin). The data contained in the melanoma databases at the participating hospitals fully comply with strict ethical requirements and are updated regularly.
Study participants
Data were collected on all patients with melanomas measuring over 4 mm from the time at which SLN biopsy was introduced at each hospital up to December 31, 2015. The procedure was introduced in different years at each center, with dates ranging from 1997 for Hospital Universitari Germans Trias i Pujol to 2004 for Hospital Universitario Virgen Macarena. Patients with clinical evidence of regional disease or distant metastases at onset were excluded. Primary tumors were excised with 2-cm margins. Patients with positive SLN findings underwent full lymphadenectomy.
The study was approved by the ethics committee at Hospital Universitari Germans Trias i Pujol.
Study groups and outcomes
The cohort of patients was first divided into patients who had undergone SLN biopsy and those who had not. The SLN biopsy group was then further divided into SLN-positive and SLN-negative patients.
The study outcomes were DFS, MSS and OS. Survival was defined as time from the date of excision of primary melanoma to the date of first recurrence at any site (for DFS), death related with melanoma (MSS), and death by any cause (OS).
The date of death due to any cause was not available for the cohort of patients from the University of Turin. For the survival analysis, these patients were censored at the time of their last visit.
Propensity score matching
Propensity score modeling is a relatively new statistical technique that controls for selection bias in studies comparing two nonrandomized treatment or intervention groups. 7 It works by matching patients according to their probability of being What's new? Sentinel lymph node biopsy, which helps identify whether melanoma has begun metastasizing, has chiefly been studied in medium thickness melanomas. How useful is it in melanomas more than 4 mm thick? Here, the authors show that performing a SLN biopsy improves disease-free survival (DFS), but not melanoma-specific survival. Those patients with a positive SLN had worse DFS than patients whose sentinel nodes were clear of cancer. Thus, they conclude, the SLN biopsy is essential for stratifying patients by risk, but not as a therapeutic tool against thick melanoma.
assigned to the SLN biopsy group or not. To create two matching groups of patients using propensity scores, we first built a logistic regression model with SLN biopsy as the dependent variable and all other variables that could potentially influence the decision to perform SLN biopsy as independent variables. These variables have all been shown to have a prognostic role in melanoma and included Breslow thickness, 8 ulceration, 8, 9 histologic regression, 10,11 microscopic satellites, 12 vascular invasion, 12 intratumoral lymphocytic infiltration, 13 anatomic-clinical subtype (nodular, superficial spreading melanoma, and others), sex, age, anatomic location, 14 hospital, year and treatment with adjuvant interferon. 15 
Statistical analysis
For between-group comparisons, the t test and MannWhitney U test were used to compare continuous variables, while the v 2 test and Fisher exact test were used to compare qualitative variables. Tumor thickness and age were logtransformed to reduce skewness.
Separate survival models were built for DFS, MSS and OS. In the three models, survival was calculated as the time from excision of the primary tumor to the event. Patients without an event were censored at the time of their last follow-up visit. The Kaplan-Meier estimator was used to construct nonparametric survival curves and the log rank test to compare curves between the SLN biopsy group and the observation group. The same method was applied for the secondary end point comparing survival curves between SLN-positive and SLNnegative patients. Univariate Cox regression models were used to determine the association between performance or nonperformance of SLN biopsy and survival. To analyze the potential effect of other factors, variables significantly associated with survival (p < 0.2) in the univariate analysis were included alongside performance or not of SLN biopsy in a multivariate Cox regression model to adjust for possible confounders.
Missing values analysis
Assuming that missing data were missing at random, we generated 20 complete datasets using multivariate imputation by chained equations (mi impute chained procedure in Stata). The procedure included all variables that were to be subsequently analyzed in addition to any variables that could help to explain the missing data. Each of 20 imputed datasets was analyzed using Cox regression to fit the model of interest to the outcome variables (DFS, MSS and OS). Finally, the results of the complete datasets were combined into a single set of estimates using Rubin rules. 16 All analyses were performed in STATA v.14.1 (Stata Corp. 2015. Stata Statistical Software: Release 14).
Results
Treatment groups
A total of 1,211 patients with thick melanomas from the 5 participating hospitals were included. Of these, 1,109 had clinically localized melanoma. SLN biopsy had been attempted in 660 patients (59%). The remaining 449 patients were included in the observation group (Supporting Information Figure S1 ).
In all, 752 patients with similar demographic and clinical characteristics were paired by propensity scores (Table 1) .
Patients were significantly older in the observation group (mean age, 65 vs. 58.2 years; p < 0.001), and in the SLN biopsy group, they had a lower proportion of head and neck tumors [17 vs . 25% (p < 0.001)] and a higher proportion of tumors on the trunk (41 vs. 34%; p < 0.001). Mean tumor thickness was slightly higher in the observation Group (6 vs. 5.8 mm; p < 0.001). Interferon therapy was more common in patients who underwent SLN biopsy (29 vs. 5%; p < 0.001). Finally, age was the only significant demographic and clinical difference between the groups matched by propensity scores, with a slightly higher mean age observed in the observation Group (66.6 vs. 64.4 years; p 5 0.032; Table 1 ).
Survival rates
Median follow-up in this propensity-matched cohort was 40 months. Just over half of the patients (n 5 421, 56%) experienced recurrence, 259 (34.4%) died of melanoma, and 300 (39.9%) died of any cause. Loss to follow-up was 22.6% (n 5 85) in the SLN biopsy group and 22.8% (n 5 86) in the observation group.
With respect to DFS, the 5-year rate was better in the SLN biopsy group than in the observation Group Fig. 1c) .
After controlling for confounders, in the multivariate analysis, SLN biopsy retained its significance as an independent predictor of DFS [adjusted HR (AHR), 0.74; 95% CI, 0.61-0.9; p 5 0.002 and OS (AHR, 0.75; 95% CI, 0.6-0.94; p 5 0.013] but not of MSS (AHR, 0.84; 95% CI, 0.65-1.08; p 5 0.165).
Other independent predictors of DFS were year of diagnosis, participating hospital, tumor thickness, ulceration, and presence of microsatellites. In the case of MSS, they were hospital, sex, tumor thickness, ulceration and microsatellites, and in the case of OS, they were hospital, sex, age, ulceration and microsatellites ( Table 2 ). The results of the crude univariate analysis for DFS, MSS and OS are shown in Supporting Information Table S1 . (Fig. 1e) .
Cancer Therapy and Prevention
Discussion
The main finding of our cohort study was that performance of SLN biopsy in patients with thick melanomas is associated with an increase in DFS but not MSS. This observation is consistent with reports from the landmark MSTL-1 trial, 1 in which 290 patients with melanomas thicker than 3.5 mm were randomized to SLN biopsy or observation. While a significant improvement was noted for DFS in those who underwent the procedure, no benefit was observed for MSS (10-year MSS, 58.9% 6 4.1 vs. 64.4% 6 4.6; p 5 0.56). This does not mean that SLN biopsy is not useful for the management of thick melanoma, as it has a role as a prognostic factor.
The emergence of SLN biopsy as a therapeutic procedure for cutaneous melanoma was prompted by what is known as the incubator hypothesis, which holds that melanoma spreads in stages, first to the sentinel nodes in the regional lymph basin and then to distant sites. 17 This theory contrasts with what is known as the marker hypothesis, which holds that metastasis occurs simultaneously via lymphatic and hematogenous routes. 18 This second theory is supported by the fact that the presence of nodal metastasis has no bearing on time to systemic metastasis. 19, 20 Our findings are more in line with the marker hypothesis as performance of SLN biopsy did not confer an MSS advantage. This concept might explain also the recent lack of advantage of the early lymphadenectomy after the presence of metastases in SLN with respect to observation provided recently by the MSLT-II 2 and
DeCOG trials, 3 despite the number of metastatic lymph node at the CLND has been described as a unfavourable prognostic marker. 21 These recent clinical trials do not support the completion of a CLND after a positive SLNB, avoiding an unnecessary surgery and complication such as lymphedema. 2, 3 SLN biopsy findings can be used to stratify patients with thick melanomas by risk. Our results show that SLN-positive patients had worse DFS and MSS than SLN-negative patients, supporting previous findings. 22 SLN status in patients with thick melanomas is therefore a useful prognostic factor for guiding the management of patients with thick melanomas, particularly considering the likely advent of new adjuvant therapies. Cancer Therapy and Prevention Table 2 . Adjusted Multivariate analysis of prognostic factors for disease-free, melanoma-specific and OS in the matching cohort (n Other factors associated with worse prognosis in our cohort study were tumor thickness, ulceration and presence of microsatellites. These are all well-known prognostic factors recognized as such by the new AJCC staging system. 6 Consistent with previous findings, 24, 25 sex was predictive of MSS and OS, while age was predictive of OS. Survival also varied among participating hospitals. MSS, for example, were better in Barcelona and Seville than in Badalona (reference category). The difference in the first case could be due to the older mean age of patients in Badalona (64 vs. 59 years for Barcelona, p 5 0.03), and in the second case, it could be due to differences in tumor thickness (7.1 mm in Badalona vs. 6.1 mm in Seville; data not shown). Significant differences were also found between hospitals for the presence of ulceration. Follow-up guidelines was similar across the hospitals.
The association between SLN biopsy and better OS may be due to a higher rate of comorbidities contraindicating this procedure in the observation group, as deaths due to other causes were more common in this group. Indications to perform the SLNB in each center depend on functional status and not on tumoral thickness. For this reason, it is justified the difference in OS and not in SSM.
The main limitation of this study is that its conclusions are based on retrospective, observational data. Propensity score modeling, however, is designed to minimize selection bias in studies comparing two nonrandomized treatment or intervention groups. 7 To provide a less-biased estimate of treatment effect, the technique uses different confounders to calculate the likelihood of each patient being assigned to one or other of the treatment groups. The patients in the resulting comparison groups therefore have very similar characteristics and the same chance of being assigned to one group or another. Our results, however, may still be affected by some bias, as even though we used propensity score matching and included many variables that potentially influence the decision whether or not to perform SLN biopsy, we did not study other variables that could affect decisions, such as patients' sociocultural level or general health status.
Another limitation is the number of included patients in matched samples. Although there is a small benefit in 5 year MSS in SLNB patients, it was not statistically significant. A benefit cannot be rule out for MSS with a large number of included patients.
However, one strength of our study is that we studied twice as many patients with thick melanomas as the MSTL-I trial. While our study was not a randomized trial, propensity score modeling is designed to simulate the effects of randomization as closely as possible. Furthermore, despite the retrospective nature of our study, the data analyzed were collected prospectively and updated regularly using national census records.
Conclusions
Our findings help to clarify the role of SLN biopsy in patients with thick melanomas. We found that the procedure increases the DFS but not the MSS in this subgroup of patients. Nonetheless, evaluation of SLN status is essential to stratify patients with thick melanomas more adequately, ultimately contributing to more effective management and follow-up.
